Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity

Keyphrases

• Therapeutic Potential 100%
• Nanomedicine 100%
• Preclinical Development 100%
• Carrier-free 100%
• Antitumor Therapeutics 100%
• Prodrug Nanoparticles 100%
• Cathepsin B 66%
• Doxorubicin 50%
• Cytotoxicity 33%
• Mass Production 33%
• Clinical Translation 33%
• Carrier Material 33%
• Retention Effect 16%
• Enhanced Retention 16%
• Tumor Targeting 16%
• Cancer Treatment 16%
• Antitumor Activity 16%
• In Cancer 16%
• Cancer Cells 16%
• Powder Form 16%
• Self-assembly 16%
• Colon Cancer 16%
• Breast Cancer 16%
• Promising Strategies 16%
• Quality Control 16%
• Drug Loading Capacity 16%
• High Drug Loading 16%
• Tumor Tissue 16%
• Permeability Effect 16%
• Enhanced Permeability 16%
• Pluronic F68 16%
• Pancreatic Cancer 16%
• Tumor Model 16%
• Technical Aspects 16%
• FDA-approved Drugs 16%
• Alternative Formulations 16%
• Potential Toxicity 16%
• Cleavage Mechanism 16%
• Lyophilized Powder 16%
• Doxorubicin Conjugates 16%
• Cleavable Peptide 16%
• Pegylated Liposomal Doxorubicin 16%
• Mass Potentials 16%
• Long-term Storage Stability 16%
• Doxil 16%
• Industrial Aspects 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Nanoparticle 100%
• Prodrug 100%
• Nanomedicine 100%
• Poloxamer 83%
• Doxorubicin 83%
• Cathepsin B 66%
• Neoplasm 33%
• Malignant Neoplasm 33%
• Cytotoxicity 33%
• Breast Cancer 16%
• Antitumor Activity 16%
• Pancreas Cancer 16%
• Tumor Model 16%
• Enhanced Permeability and Retention Effect 16%
• Colon Carcinoma 16%